Srishti Kotiyal

Srishti Kotiyal, PhD, is a Private Equity Associate at Ally Bridge Group in New York, where she concentrates on private equity investments in the biotechnology sector. Her role involves sourcing, evaluating, and executing investments in innovative biotech companies, leveraging her deep scientific and financial expertise.

Prior to joining Ally Bridge Group in 2024, Srishti was an Associate in the Healthcare Investment Banking Group at Jefferies, where she focused on advising biotechnology clients on equity financings and M&A transactions. She gained additional experience in healthcare and life sciences investing through roles at Eventide Asset Management and Sorenson Impact, working in both public and private markets with a particular emphasis on medtech and impact-driven startups.

Srishti holds a PhD in Oncological Sciences from the University of Utah's Huntsman Cancer Institute and a Bachelor of Technology in Biotechnology from Jaypee Institute of Information Technology. She has authored ten peer-reviewed publications in cancer biology and environmental biotechnology, with over 270 citations, underscoring her technical contributions and credibility in the life sciences investment field.